A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

BACKGROUND: Masitinib is a selective oral tyrosine–kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: Patients with inoperable, chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516046/
https://www.ncbi.nlm.nih.gov/pubmed/25858497
http://dx.doi.org/10.1093/annonc/mdv133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516046/
https://www.ncbi.nlm.nih.gov/pubmed/25858497
http://dx.doi.org/10.1093/annonc/mdv133

Ejemplares similares